Antheia Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Private

  • Employees
  • 65

Employees

  • Latest Deal Type
  • Series C

  • Latest Deal Amount
  • $80M

  • Investors
  • 23

Antheia General Information

Description

Operator of a biotechnology company intended to develop plant-inspired medicines. The company's cost-competitive, plant-based medicines are made using synthetic biology, informatics, and fermentation technology to harness beneficial molecules from plants to create active pharmaceutical ingredients, enabling healthcare organizations to provide patients with natural and healthier medication.

Contact Information

Website
www.antheia.bio
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 1430 O'Brien Drive
  • Suite A
  • Menlo Park, CA 94025
  • United States
+1 (650)
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Pharmaceuticals
Vertical(s)
Corporate Office
  • 1430 O'Brien Drive
  • Suite A
  • Menlo Park, CA 94025
  • United States
+1 (650)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Antheia Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
12. Later Stage VC (Series C) 27-Jan-2026 $80M Completed Generating Revenue
11. Later Stage VC (Series B) 30-Jun-2021 Completed Product Development
10. Debt - PPP 13-Apr-2020 Completed Product Development
9. Debt - General 31-Dec-2019 Completed Product Development
8. Debt - General 01-Dec-2018 Completed Product Development
7. Later Stage VC (Series B) 04-Sep-2018 Completed Product Development
6. Grant 01-Jan-2018 Completed Startup
5. Early Stage VC (Series A) 26-May-2017 Completed Startup
4. Grant 01-Jan-2017 $900K $1.97M Completed Startup
3. Grant 01-Jan-2016 $450K $1.97M Completed Startup
To view Antheia’s complete valuation and funding history, request access »

Antheia Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C-1
Series C-2
Series B-3
Series B-2
Series B-1
Series A 2,791,257 $0.000100 $0.71 $8.6 $8.6 1x $8.6 1.39%
Seed 2,237,533 $0.000100 $0.09 $1.12 $1.12 1x $1.12 1.11%
To view Antheia’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Antheia Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a biotechnology company intended to develop plant-inspired medicines. The company's cost-competitive, plant-
Biotechnology
Menlo Park, CA
65 As of 2026

Bedford, MA
 

Brisbane, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Antheia Competitors (3)

One of Antheia’s 3 competitors is Conagen, a Corporate Backed or Acquired company based in Bedford, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Conagen Corporate Backed or Acquired Bedford, MA
Mammoth Biosciences Venture Capital-Backed Brisbane, CA
Biosyntia Venture Capital-Backed Copenhagen, Denmark
You’re viewing 3 of 3 competitors. Get the full list »

Antheia Patents

Antheia Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4594342-A2 Methods of improving production of morphinan alkaloids and derivatives Pending 29-Sep-2022
US-20260103736-A1 Methods of improving production of morphinan alkaloids and derivatives Pending 29-Sep-2022
WO-2024073755-A2 Methods of improving production of morphinan alkaloids and derivatives Inactive 29-Sep-2022
WO-2024073755-A3 Methods of improving production of morphinan alkaloids and derivatives Inactive 29-Sep-2022
US-12409144-B2 Oxygen capsule as well as preparation method and application thereof Active 19-Oct-2021 A61K9/4833
To view Antheia’s complete patent history, request access »

Antheia Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Antheia Investors (23)

Investor Name Investor Type Holding Investor Since Participating Rounds
America's Frontier Fund Venture Capital Minority
Athos (Family Office) Family Office Minority
Civilization Ventures Venture Capital Minority
Echo Investment Capital PE/Buyout Minority
EDBI Venture Capital Minority
You’re viewing 5 of 23 investors. Get the full list »

Antheia FAQs

  • When was Antheia founded?

    Antheia was founded in 2013.

  • Where is Antheia headquartered?

    Antheia is headquartered in Menlo Park, CA.

  • What is the size of Antheia?

    Antheia has 65 total employees.

  • What industry is Antheia in?

    Antheia’s primary industry is Biotechnology.

  • Is Antheia a private or public company?

    Antheia is a Private company.

  • What is the current valuation of Antheia?

    The current valuation of Antheia is .

  • What is Antheia’s current revenue?

    The current revenue for Antheia is .

  • How much funding has Antheia raised over time?

    Antheia has raised $176M.

  • Who are Antheia’s investors?

    America's Frontier Fund, Athos (Family Office), Civilization Ventures, Echo Investment Capital, and EDBI are 5 of 23 investors who have invested in Antheia.

  • Who are Antheia’s competitors?

    Conagen, Mammoth Biosciences, and Biosyntia are competitors of Antheia.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process